| 2.82 Delayed Data As of Jul 22 |  +0.03 / +1.08%Today’s Change | 2.15 Today|||52-Week Range 6.30 | -29.50% Year-to-Date |
| Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs Jul 17 / Zacks.com - Paid Partner Content | Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 Jul 09 / Zacks.com - Paid Partner Content |
| Why Inovio Pharmaceuticals Stock Is Plunging Today Jul 17 / MotleyFool.com - Paid Partner Content |
| Previous close | 2.79 |
| Today’s open | 2.80 |
| Day’s range | 2.77 - 2.86 |
| Volume | 443,444 |
| Average volume (3 months) | 1,122,616 |
| Market cap | $274.0M |
| Earnings growth (last year) | +2.98% |
| Earnings growth (this year) | +5.53% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -27.80% |
| P/E ratio | NM |
| Price/Sales | 12.14 |
| Price/Book | 3.13 |
| Today’s change | Today’s % change | |
|---|---|---|
| VRCAVerrica Pharmaceutic... | -0.24 | -2.32% |
| EIGREiger BioPharmaceuti... | -0.03 | -0.28% |
| LOGCLogicBio Therapeutic... | +0.33 | +2.60% |
| PHASPhaseBio Pharmaceuti... | -0.23 | -2.29% |
| Next reporting date | August 5, 2019 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $30.5M |
| Annual profit (last year) | -$97.0M |
| Net profit margin | -318.12% |
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director J. Joseph Kim |
Chief Operating Officer & Executive Vice President Jacqueline E. Shea |
Corporate headquarters Plymouth Meeting, Pennsylvania |
